PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Endocrine-Related Cancer · 2026
DOI: 10.1530/erc-25-0495 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Virginia Corbett und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms, Intestinal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuroendocrine tumors (NETs) are rare, heterogeneous neoplasms with varying prognoses and management approaches. Peptide receptor radionuclide therapy (PRRT), targeting tumors expressing somatostatin receptors, delivers cytotoxic radiation to tumor cells. While PRRT has demonstrated efficacy in advanced, well-differentiated NETs, the optimal sequencing with other therapies remains an area of active research. This review explores PRRT’s role in NET management, focusing on its mechanisms, clinical efficacy, safety profile, and integration into a multi-modal treatment strategy. We also examine evidence on the sequencing of PRRT with surgery, liver-directed therapy, chemotherapy, and targeted therapies to optimize treatment outcomes. We conducted a comprehensive review of recent clinical trials, cohort studies, and expert consensus guidelines to assess PRRT’s place in the treatment paradigm. Factors influencing treatment sequencing, such as tumor type, receptor expression, disease burden, and patient-specific characteristics, are also discussed. PRRT has proven effective for patients with advanced, somatostatin receptor-positive NETs, especially for inoperable tumors or those progressing after other therapies. While PRRT plays a vital role in management, its sequencing with other treatments remains complex, with evidence supporting its use both early and late in treatment based on individual patient factors. Optimizing its sequencing with other treatments requires further research but offers potential for improved outcomes. A personalized, multidisciplinary approach is essential for maximizing PRRT’s benefits in NET management. This review article summarizes current evidence and describes patient-specific circumstances, enabling treatment provider to make informed PRRT sequencing decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Hematology and Oncology, Helen Diller Family Comprehensive Cancer Center, UCSF, CA.
ORCID-Profile: Aman Chauhan
Zitieren
APA
Corbett, V., Gupta, G., & Chauhan, A. (2026). PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0495
Vancouver
Corbett V, Gupta G, Chauhan A. PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Endocrine-Related Cancer. 2026. doi:10.1530/erc-25-0495
BibTeX
@article{Corbett2026,
author = {Corbett, Virginia and Gupta, Garima and Chauhan, Aman},
title = {PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)},
journal = {Endocrine-Related Cancer},
year = {2026},
doi = {10.1530/erc-25-0495}
}
EUVIMED